Moderna. has filed a patent for broad spectrum influenza virus ribonucleic acid (RNA) vaccines. The patent also covers methods of using the vaccines and compositions comprising them. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of September 2023 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Broad spectrum influenza virus rna vaccines and methods of use
A recently filed patent (Publication Number: US20230310576A1) describes an influenza virus vaccine that utilizes ribonucleic acid (RNA) polynucleotides to encode influenza virus antigenic polypeptides. The vaccine is formulated in a lipid nanoparticle and can be multivalent, providing protection against multiple influenza strains. The vaccine also includes compounds of Formula (I), which are used to enhance cross-reactivity against a variety of influenza strains. The lipid nanoparticle formulation includes a combination of cationic lipid, PEG-modified lipid, sterol, and non-cationic lipid. The nanoparticle has a net neutral charge at a neutral pH value and a polydispersity value of less than 0.4. The RNA polynucleotides may also include chemical modifications such as pseudouridine, N1-methylpseudouridine, and 2-thiouridine.
The vaccine can induce an immune response in a subject, including both T cell and B cell responses. It is administered to the subject in an amount effective to produce an antigen-specific immune response. Additionally, the vaccine can induce cross-reactivity against a variety of influenza strains in a mammal. This can be achieved by administering at least two RNA polynucleotides encoding consensus hemagglutinin antigens separately or simultaneously. The vaccine includes consensus hemagglutinin antigens, as well as other influenza virus antigenic polypeptides such as neuraminidase, nucleoprotein, matrix protein 1, matrix protein 2, non-structural protein 1, and non-structural protein 2. The vaccine can be formulated to target specific influenza virus strains, including H1, H2, H3, H5, H7, H9, and H10 subtypes.
The lipid nanoparticle formulation of the vaccine plays a crucial role in its efficacy. It includes a specific molar ratio of cationic lipid, PEG-modified lipid, sterol, and non-cationic lipid. The nanoparticle has a polydispersity value of less than 0.4 and a net neutral charge at a neutral pH value. These characteristics contribute to the stability and effectiveness of the vaccine. The RNA polynucleotides used in the vaccine may also undergo chemical modifications to enhance their performance. These modifications include pseudouridine, N1-methylpseudouridine, and 2-thiouridine, among others.
Overall, this patent describes a promising influenza virus vaccine that utilizes RNA polynucleotides and a lipid nanoparticle formulation to induce an immune response and cross-reactivity against multiple influenza strains. The specific formulation and chemical modifications contribute to the vaccine's stability and efficacy. Further research and development based on this patent could lead to improved influenza vaccines with broader protection against different strains.
To know more about GlobalData’s detailed insights on Moderna, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
